Sphera Funds Management’s Janux Therapeutics JANX Stock Holding History

Sphera Funds Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-157,840	Closed	-$2.18M	–	105
2025 Q4	$2.18M	Buy	157,840 +72,000	+84%	+$1.69M	0.42%	72
2025 Q3	$2.1M	Hold	85,840	–	–	0.44%	73
2025 Q2	$1.98M	Sell	85,840 -40,000	-32%	-$1.05M	0.47%	70
2025 Q1	$3.4M	Buy	125,840 +57,507	+84%	+$2.17M	0.78%	40
2024 Q4	$3.66M	Buy	+68,333	New	+$3.61M	0.66%	58

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sphera Funds Management's JANX Position: Q1 2026 in Review

Sphera Funds Management sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 157,840 shares — an estimated $2.18M sold.

Sphera Funds Management first reported a position in JANX in Q4 2024 and held it in 5 quarters. The position peaked at $3.66M in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Sphera Funds Management reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
Sphera Funds Management sold 157,840 Janux Therapeutics shares in Q1 2026, an estimated $2.18M.
Sphera Funds Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 5 quarters.
Sphera Funds Management's Janux Therapeutics position peaked at $3.66M in Q4 2024.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.